Every material Form 8-K Cardio Diagnostics Holdings, Inc. has filed with the SEC since May 28, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cardio Diagnostics Holdings (NASDAQ: CDIO) filed an 8-K stating that from August 20, 2026, senior management will use an August 2026 investor presentation with existing and prospective investors, and that it will be posted on the company's website. The presentation covers reimbursement milestones, lab operations and market opportunity, but the filing itself reports no revenue, earnings, or guidance, and the company states it is not providing guidance.
Investor presentation (Exhibit 99.1) to be used from August 20, 2026, and posted at www.cdio.ai
Presentation states the Company is not making projections or providing guidance on future results
Reimbursement: CMS final payment rate of $854 per test set December 2025; Medicare coverage determination in progress
Presentation cites an internal estimate of about $125 billion total addressable US market for Epi+Gen CHD and about $51 billion for PrecisionCHD, and notes market opportunity reflects potential, not current revenue
Cardio Diagnostics Holdings, Inc. (CDIO) filed an 8-K to announce an investor conference call on February 19, 2026 to discuss its current status, recent developments and strategic priorities. The filing includes a slide presentation as Exhibit 99.1 but no financial results, and the company states it is not providing guidance on future results, so shareholders can use the materials to review reimbursement, clinical data and lab progress.
Investor call set for 3 p.m. Central Standard Time on February 19, 2026, covering recent clinical data, reimbursement progress and strategic initiatives
Presentation furnished as Exhibit 99.1; replay to be available on the investor relations website for a limited time
Presentation says Medicare coverage process is ongoing and out-of-network billing capability is expected in Q2 2026
The company states it is not making projections or providing guidance on future consolidated results
Cardio Diagnostics Holdings received written notice from Nasdaq on May 28, 2025, that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The closing bid price was $1.00 or greater for the 10 consecutive business days from May 13 through May 27, 2025. The notice removes the risk of delisting that had been pending under the extended compliance period ending June 2, 2025.
Nasdaq notice dated May 28, 2025 confirms regained compliance with the minimum bid price rule (Listing Rule 5550(a)(2)).
Compliance is based on closing bid prices of $1.00 or greater from May 13, 2025 through May 27, 2025.
The company had been given until June 2, 2025 to regain compliance, following an initial December 2, 2024 deadline.
The non-compliance notice was first received on June 3, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cardio Diagnostics Holdings, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →